Literature DB >> 17999628

Targeting the mitochondria for cancer therapy: regulation of hypoxia-inducible factor by mitochondria.

Eric L Bell1, Tatyana Klimova, Navdeep S Chandel.   

Abstract

As tumors develop, they outgrow the vascular network that supplies cells with oxygen and nutrients needed for survival. In response to decreased oxygen levels, the tumor cells initiate a program of adaptation by inducing the transcription of multiple genes via the activation of the transcription factor hypoxia-inducible factor (HIF). Proteins encoded by a subset of genes induced by HIF promote tumorigenesis by acting directly on both the tumor cells and the microenvironment in which the tumor cells reside. The mechanism(s) by which hypoxia activates HIF is a subject of intensive research. Understanding how hypoxia activates HIF will provide targets for the development of therapies that could specifically target growing tumors by not allowing adequate adaptation to hypoxia, which is necessary for cancer progression. Here we outline how mitochondria regulate the activity of HIF during hypoxia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17999628     DOI: 10.1089/ars.2007.1655

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  12 in total

1.  Marine Natural Products as Inhibitors of Hypoxic Signaling in Tumors.

Authors:  Dale G Nagle; Yu-Dong Zhou
Journal:  Phytochem Rev       Date:  2009-06       Impact factor: 5.374

Review 2.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

3.  Molecular-targeted antitumor agents. 19. Furospongolide from a marine Lendenfeldia sp. sponge inhibits hypoxia-inducible factor-1 activation in breast tumor cells.

Authors:  Yang Liu; Rui Liu; Shui-Chun Mao; J Brian Morgan; Mika B Jekabsons; Yu-Dong Zhou; Dale G Nagle
Journal:  J Nat Prod       Date:  2008-11-06       Impact factor: 4.050

4.  Signaling pathway networks mined from human pituitary adenoma proteomics data.

Authors:  Xianquan Zhan; Dominic M Desiderio
Journal:  BMC Med Genomics       Date:  2010-04-28       Impact factor: 3.063

Review 5.  Relevance of mitochondrial genetics and metabolism in cancer development.

Authors:  Giuseppe Gasparre; Anna Maria Porcelli; Giorgio Lenaz; Giovanni Romeo
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-02-01       Impact factor: 10.005

Review 6.  Multi-functional nanocarriers to overcome tumor drug resistance.

Authors:  Lara S Jabr-Milane; Lilian E van Vlerken; Sunita Yadav; Mansoor M Amiji
Journal:  Cancer Treat Rev       Date:  2008-06-05       Impact factor: 12.111

7.  MnSOD upregulation sustains the Warburg effect via mitochondrial ROS and AMPK-dependent signalling in cancer.

Authors:  Peter C Hart; Mao Mao; Andre Luelsdorf P de Abreu; Kristine Ansenberger-Fricano; Dede N Ekoue; Douglas Ganini; Andre Kajdacsy-Balla; Alan M Diamond; Richard D Minshall; Marcia E L Consolaro; Janine H Santos; Marcelo G Bonini
Journal:  Nat Commun       Date:  2015-02-05       Impact factor: 14.919

8.  mtDNA depletion confers specific gene expression profiles in human cells grown in culture and in xenograft.

Authors:  Darren Magda; Philip Lecane; Julia Prescott; Patricia Thiemann; Xuan Ma; Patricia K Dranchak; Donna M Toleno; Krishna Ramaswamy; Kimberly D Siegmund; Joseph G Hacia
Journal:  BMC Genomics       Date:  2008-11-03       Impact factor: 3.969

9.  The use of variations in proteomes to predict, prevent, and personalize treatment for clinically nonfunctional pituitary adenomas.

Authors:  Xianquan Zhan; Dominic M Desiderio
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

10.  Moderating effects of sleep duration on diabetes risk among cancer survivors: analysis of the National Health Interview Survey in the USA.

Authors:  Azizi A Seixas; Lloyd Gyamfi; Valerie Newsome; Gabrielle Ranger-Murdock; Mark Butler; Diana Margot Rosenthal; Ferdinand Zizi; Irini Youssef; Samy I McFarlane; Girardin Jean-Louis
Journal:  Cancer Manag Res       Date:  2018-10-12       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.